PDCD1 and carcinoma: In the syngeneic KPL model, AXL inhibitor acts primarily on DCs, rather than on carcinoma cells or macrophages, promoting DC-mediated type I interferon secretion, infiltration of the TCF1+PD-1+CD8 cells, and response to anti-PD-1.